Overactive Bladder - Pipeline Review, H1 2012

Global Markets Direct, March 2012, Pages: 101

Overactive Bladder – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H1 2012', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Overactive Bladder. 'Overactive Bladder - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Overactive Bladder.
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Overactive Bladder therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Overactive Bladder Therapeutic Products under Development, Key Players in Overactive Bladder Therapeutics, Overactive Bladder Pipeline Overview, Overactive Bladder Pipeline, Overactive Bladder Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Overactive Bladder Overview
Therapeutics Development
An Overview of Pipeline Products for Overactive Bladder
Overactive Bladder Therapeutics under Development by Companies
Overactive Bladder Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Overactive Bladder Therapeutics – Products under Development by Companies
Overactive Bladder Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Overactive Bladder Therapeutics Development
Allergan, Inc.
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
American Oriental Bioengineering, Inc.
Astellas Pharma Inc.
Auxilium Pharmaceuticals, Inc.
Recordati S.p.A.
Teva Pharmaceutical Industries Limited
Addex Pharmaceuticals
Hisamitsu Pharmaceutical Co., Inc.
Urigen Pharmaceuticals, Inc.
Plethora Solutions Holdings plc
KeyNeurotek Pharmaceuticals AG
PharmEste
Pear Tree Pharmaceuticals
Hydra Biosciences, Inc.
Mt Cook Pharma. Inc.
Overactive Bladder – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SMP-986 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM905 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Betanis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AA4010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC 0422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC 1819 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
URG302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEN-D0501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KN203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-4618 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN-214868 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCP-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AOBO-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bryophyllum Pinnatum - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DR-3001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC 0436 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRPs antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Of TRPV1 Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposome Encapsulated Botulinum Toxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tolterodine + Tamsulosin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TD9594 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-101a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Targeted Toxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HOB-294 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GABA-BR PAM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-259 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diltiazem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Overactive Bladder Therapeutics – Drug Profile Updates
Overactive Bladder Therapeutics – Discontinued Products
Overactive Bladder Therapeutics - Dormant Products
Overactive Bladder – Product Development Milestones
Featured News & Press Releases
Dec 08, 2011: Antares's Oxybutynin Gel Product Receives FDA Approval For Treatment Of Overactive Bladder
Nov 23, 2011: Provesica Publishes XEN-D0501 Phase I Data On Innovative New Medicine For Overactive Bladder
Nov 11, 2011: Astellas Announces Receipt Of Filing Communication Letter From FDA Regarding Mirabegron
Aug 29, 2011: Astellas Pharma Announces Regulatory Submissions For Mirabegron For Overactive Bladder In US And Europe
Jul 01, 2011: Astellas Receives Approval For Betanis Tablet In Japan For Overactive Bladder
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence
Apr 20, 2011: Astellas Launches Orally Disintegrating Vesicare OD Tablet In Japan
Apr 05, 2011: Ono Pharmaceutical Launches Orally Disintegrating Tablet Of Staybla Tablets 0.1mg For Overactive Bladder
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Overactive Bladder, H1 2012
Products under Development for Overactive Bladder – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Allergan, Inc., H1 2012
Merck & Co., Inc., H1 2012
Dainippon Sumitomo Pharma Co., Ltd., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
American Oriental Bioengineering, Inc., H1 2012
Astellas Pharma Inc., H1 2012
Auxilium Pharmaceuticals, Inc., H1 2012
Recordati S.p.A., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Addex Pharmaceuticals, H1 2012
Hisamitsu Pharmaceutical Co., Inc., H1 2012
Urigen Pharmaceuticals, Inc., H1 2012
Plethora Solutions Holdings plc, H1 2012
KeyNeurotek Pharmaceuticals AG, H1 2012
PharmEste, H1 2012
Pear Tree Pharmaceuticals, H1 2012
Hydra Biosciences, Inc., H1 2012
Mt Cook Pharma. Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Overactive Bladder Therapeutics – Drug Profile Updates
Overactive Bladder Therapeutics – Discontinued Products
Overactive Bladder Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Overactive Bladder, H1 2012
Products under Development for Overactive Bladder – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Global Overactive Bladder Drug Pipeline Capsule - 2012
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• U.S. Overactive Bladder Market
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013